잠복결핵의 진단과 치료: 2017 개정 지침을 중심으로
Diagnosis and Treatment of Latent Tuberculosis Infection: The Updated 2017 Korean Guidelines
1
조회
0
다운로드
11
인용
0
참고문헌
키워드
초록
A small number of viable tuberculosis bacilli can reside in an individual with latent tuberculosis infection (LTBI) without obvious clinical symptoms or abnormal chest radiographs. Diagnosis and treatment of LTBI are important for tuberculosis (TB) control in public and private healthcare facilities, particularly in high-risk populations. The updated 2017 Korean guidelines for TB recommend that tuberculin skin tests, interferon-gamma release assays, or a combination of them can be used for the diagnosis of LTBI, depending on the age and immune status of the patient as well as their TB contact history. For diagnosis of LTBI, exclusion of active TB is essential, and the possibility of healed TB in those without a history of treatment for TB but at risk of its development must be considered. The treatment options for LTBI include isoniazid, rifampicin, isoniazid/rifampicin, and isoniazid/rifapentine. The benefits and risks of these agents based on the age of the patient and their hepatotoxicity must be considered when selecting the appropriate drug. Standardized diagnosis and treatment of LTBI based on the updated 2017 guidelines will contribute to the control of TB in Korea as well as to further revisions of the guidelines.
Abstract
A small number of viable tuberculosis bacilli can reside in an individual with latent tuberculosis infection (LTBI) without obvious clinical symptoms or abnormal chest radiographs. Diagnosis and treatment of LTBI are important for tuberculosis (TB) control in public and private healthcare facilities, particularly in high-risk populations. The updated 2017 Korean guidelines for TB recommend that tuberculin skin tests, interferon-gamma release assays, or a combination of them can be used for the diagnosis of LTBI, depending on the age and immune status of the patient as well as their TB contact history. For diagnosis of LTBI, exclusion of active TB is essential, and the possibility of healed TB in those without a history of treatment for TB but at risk of its development must be considered. The treatment options for LTBI include isoniazid, rifampicin, isoniazid/rifampicin, and isoniazid/rifapentine. The benefits and risks of these agents based on the age of the patient and their hepatotoxicity must be considered when selecting the appropriate drug. Standardized diagnosis and treatment of LTBI based on the updated 2017 guidelines will contribute to the control of TB in Korea as well as to further revisions of the guidelines.
참고문헌 (26)
- Frieden TR, "Tuberculosis", Lancet, 362, pp.887~899 (2003)
- WHO, "Global tuberculosis control" (2011), World Health Organization
- Global tuberculosis report 2017, "WHO", World Health Organization, ~ (2018)
- Lewinsohn DM, "Official American Thoracic Society", Infectious Diseases Society of America, Clin Infect Dis, pp.2017, 64[DOI]
- "Clinical guideline 33. Tuberculosis. Clinical diagnosis and management of Tuberculosis, and Measures for its Prevention and Control" (2016)[URL]
- "Korean Guidelines for Tuberculosis" (2011)[URL]
- "Korean Guidelines for Tuberculosis" (2017)[URL]
- Hong YP, "The seventh nationwide tuberculosis prevalence survey in Korea", Int J Tuberc Lung Dis, 2, pp.27~36 (1995)
- Choi CM, "The role of TST in the diagnosis of latent tuberculosis infection among military personnel in South Korea", Int J Tuberc Lung Dis, 10, pp.1342~1346 (2006)
- Lee JY, "Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection", Eur Respir J, 28, pp.24~30 (2006)
- Lee SW, "Tuberculin skin test distribution following a change in BCG vaccination policy", PLoS One, 9, pp.e86419~ (2014)
- Targeted tuberculin testing, "This is a joint statement of the American thoracic society (ATS) and the centers for disease control and prevention (CDC). This statement was endorsed by the council of the infectious diseases society of America. (IDSA), September 1999, and the sections of this statement", Am J Respir Crit Care Med, 161(4 Pt 2), pp.S221~S247 (2000)
- Solovic I, "The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement", Eur Respir J, 36, pp.1185~1206 (2010)
- Metcalfe JZ, "Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice", Am J Respir Crit Care Med, 187, pp.206~211 (2013)
- Pulblic Health Agency of Canada, "Canadian tuberculosis standard" (2014), Centre for Disease Control
- Mazurek GH, "Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States, 2010", MMWR Recomm Rep, 59(RR-5), pp.1~25 (2010)
- National Tuberculosis Controllers Association, "Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the national tuberculosis controllers association and CDC", MMWR Recomm Rep, 54(RR-15), pp.1~47 (2005)
- Menzies D, "Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults", N Engl J Med, 379, pp.440~453 (2018)
- Spyridis NP, "The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study", Clin Infect Dis, 45, pp.715~722 (2007)
- Sterling TR, "Three months of rifapentine and isoniazid for latent tuberculosis infection", N Engl J Med, 365, pp.2155~2166 (2011)
- Kim SH, "A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients", Am J Transplant, 11, pp.1927~1935 (2011)
- Kim SY, "Comparison of the tuberculin skin test and interferon-γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation", Infection, 41, pp.103~110 (2013)
- Kim SH, "Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation", Transpl Infect Dis, 12, pp.113~119 (2010)
- 조경욱, "Prevalence of Latent Tuberculosis Infection among Health Care Workers in South Korea: A Multicenter Study", Tuberculosis and Respiratory Diseases, 75(1), pp.18~24 (2013), 대한결핵및호흡기학회
- Kim SJ, "Risk of occupational tuberculosis in national tuberculosis programme laboratories in Korea", Int J Tuberc Lung Dis, 11, pp.138~142 (2007)
- "2018 manual of national tuberculosis control" (2018)[URL]